SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-014041 to Scorpius Holdings, Inc. (SCPX) (CIK 0001476963) (SCPX)

Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)
Date: Dec. 19, 2024 · CIK: 0001476963 · Accession: 0000000000-24-014041

AI Filing Summary & Sentiment

File numbers found in text: 333-283880

Date
December 19, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)

Letter

December 19, 2024 Jeffrey Wolf Chief Executive Officer Scorpius Holdings, Inc. 627 Davis Drive, Suite 300 Morrisville, North Carolina 27560 Re:Scorpius Holdings, Inc. Registration Statement on Form S-1 Filed December 18, 2024 File No. 333-283880 Dear Jeffrey Wolf: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Melissa Palat Murawsky, Esq.

Show Raw Text
December 19, 2024
Jeffrey Wolf
Chief Executive Officer
Scorpius Holdings, Inc.
627 Davis Drive, Suite 300
Morrisville, North Carolina 27560
Re:Scorpius Holdings, Inc.
Registration Statement on Form S-1
Filed December 18, 2024
File No. 333-283880
Dear Jeffrey Wolf:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Melissa Palat Murawsky, Esq.